Similarly, imipramine, a TCA, inhibits ERK/NF-κB signaling, thereby impeding glioma cell invasion, angiogenesis, and proliferation, and this therapeutic efficacy was validated in a glioblastoma-bearing mouse model (10 mg/kg imipramine every day for mouse).9 In summary, numerous studies have elucidated the anti-glioma effects of some kinds of antidepressants at the preclinical level.10–15. The gene discussed is NFKB1; the disease is glioma.